For vasodilatory shock. ANDA 214314, held by Eugia Pharma. Vasopressin.
As of Nov 15, 2026, ANDA 214314 (Vasopressin), held by Eugia Pharma, was first approved by FDA on Aug 15, 2022, with 0 approved supplements and 0 published complete response letters.
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vasopressin20UNITS/ML (20UNITS/ML) · solution;intravenous | Vasopressin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
